Sermorelin – 10mg

Researchers who buy Sermorelin research peptide are typically studying its behavior as a truncated analog of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic signal that stimulates growth-hormone release from the pituitary. Sermorelin — also referenced in the literature as GHRH(1-29) or GRF(1-29) — is the shortest synthetic fragment reported to retain the full biological activity of native GHRH. The summary below reflects the published preclinical and clinical literature and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

In this reference:

• What Is Sermorelin?
• Proposed Mechanism of Action
• Chemical Identity
• Purity, Storage & Quality
• Research Applications
• What the Human Evidence Shows
• Compared to Related Research Compounds
• Frequently Asked Questions

What Is Sermorelin?

Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal fragment of human growth hormone-releasing hormone — the first 29 residues of the native 44-amino-acid GHRH molecule, commonly written as GHRH(1-29)-NH2 or GRF(1-29). Published pharmacology literature describes this truncated fragment as retaining the full receptor-binding and growth-hormone-releasing activity of the intact native hormone, which is why it became the standard synthetic research and diagnostic tool for studying the GHRH signaling axis.

Because Sermorelin acts on the same receptor as endogenous GHRH, it is studied in the literature both as a diagnostic probe of pituitary somatotroph function and as a research tool for characterizing hypothalamic-pituitary GH-axis signaling more broadly. Researchers sourcing this compound are typically studying GHRH-receptor pharmacology and pulsatile GH-axis physiology, not a general secretagogue effect.

Proposed Mechanism of Action

Published research describes Sermorelin as binding to the growth-hormone-releasing hormone receptor (GHRHR), a G-protein-coupled receptor expressed on somatotroph cells in the anterior pituitary. Receptor activation stimulates adenylate cyclase and increases intracellular cyclic AMP (cAMP), which in tested models triggers synthesis and pulsatile secretion of growth hormone from the pituitary into circulation.

This mechanism is distinct from that of ghrelin-receptor (GHS-R1a) secretagogues such as Ipamorelin — GHRH-receptor agonists like Sermorelin act on a separate receptor and signaling cascade, which is why researchers frequently study the two classes in comparative or combined protocols. Because Sermorelin preserves the endogenous, hypothalamically-regulated pulsatile release pattern rather than driving continuous receptor stimulation, published literature has proposed it as a tool for studying physiologic GH-axis regulation specifically, as distinct from supraphysiologic secretagogue stimulation.

Sermorelin’s short circulating half-life — a consequence of rapid enzymatic degradation of the native GHRH(1-29) sequence — is itself a subject of research interest, and is part of why later GHRH-analog research compounds (including Tesamorelin and CJC-1295, referenced below) were developed with structural modifications intended to extend receptor engagement in tested models.

Chemical Identity

Other Names	GHRH(1-29), GRF(1-29), Geref
Molecular Formula	C149H246N44O42S
Molecular Weight	~3357.9 g/mol
Sequence Length	29 amino acids
Appearance	White to off-white lyophilized powder

Purity, Storage & Quality

First Class Science supplies this Sermorelin research peptide vial at research-grade purity, verified by independent third-party HPLC testing and mass spectrometry. A Certificate of Analysis is available for every batch at our Certificate of Analysis page, listing the specific lot’s purity result, molecular-weight confirmation, and test date.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions, both of which are associated with accelerated peptide degradation in handling literature.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Preparing Solutions for Laboratory Use

Laboratories reconstituting lyophilized Sermorelin for in vitro or animal-model research typically follow standard peptide-handling practice: the vial is brought to room temperature before opening, and a diluent — commonly reconstitution solution or sterile water for injection (SWFI) — is added slowly down the interior wall of the vial rather than directly onto the lyophilized material, to reduce foaming and mechanical stress on the peptide. The vial is then gently swirled, never shaken, until the powder is fully dissolved.

Stock-solution concentration for a given protocol is calculated by dividing the total peptide mass in the vial by the volume of diluent added, and that calculation should be recorded in the study’s protocol documentation. This page describes general laboratory reconstitution practice for research use and is not a dosing guide for human or animal administration.

Quality Control Methodology

Each production batch of this Sermorelin research peptide undergoes independent third-party testing before release. High-performance liquid chromatography (HPLC) confirms purity by measuring the proportion of the target peptide relative to synthesis by-products or degradation fragments. Mass spectrometry separately confirms molecular identity, verifying that the measured mass of the material matches the expected ~3357.9 g/mol molecular weight of Sermorelin. Both results are recorded on the batch’s published Certificate of Analysis, letting researchers independently verify identity and purity rather than relying on manufacturer claims alone.

Who Should Buy Sermorelin Research Peptide

Researchers who buy Sermorelin from First Class Science are typically university and academic laboratories, contract research organizations (CROs), and biotechnology R&D teams running in vitro receptor-binding assays or animal-model studies on GHRH-receptor pharmacology and GH-axis signaling. First Class Science requires that all research-peptide orders be placed by parties who acknowledge and agree to the research-use-only terms stated on this page prior to purchase.

Research Applications

The published literature on Sermorelin/GHRH(1-29) spans several distinct research areas. Each is summarized below strictly as a description of what has been studied in animal, in vitro, or controlled clinical-trial models — not as a claim about effects for any individual using this product.

GHRH-Receptor Pharmacology Research

Because Sermorelin is the shortest fragment reported to retain full native GHRH activity, it is used as a reference compound in receptor-binding and structure-activity research on the GHRHR receptor, helping characterize how synthetic GHRH analogs engage the same pituitary signaling pathway as the endogenous 44-amino-acid hormone.

Pediatric Growth Hormone Deficiency Research

Sermorelin’s most extensively published clinical research examined its use in children with growth hormone deficiency of hypothalamic origin. A randomized controlled trial assigned 43 prepubertal children with GH deficiency to low-dose GHRH(1-29)-NH2, high-dose GHRH(1-29)-NH2, or growth hormone itself over a 6-month treatment period, comparing growth-response measures across groups (Thorner MO, et al., PMID 8329826). A related randomized trial in 60 children with hypothalamic-origin GH deficiency compared the same GHRH(1-29)-NH2 dosing regimens against GH administration directly (PMID 8329830).

Diagnostic Pituitary-Function Research

Separate published literature has examined intravenous GHRH(1-29) administration as a diagnostic stimulation test for assessing pituitary somatotroph reserve and diagnosing growth hormone deficiency, a research and clinical-diagnostic application distinct from any therapeutic-development program.

What the Human Evidence Shows

Researchers evaluating Sermorelin should know that a substantial body of controlled human clinical research exists on this molecule — considerably more than for many later-generation GH-axis research peptides — because Sermorelin (marketed historically under the name Geref) was developed and studied by a pharmaceutical sponsor as a diagnostic and potential therapeutic agent for pediatric growth hormone deficiency. A published review summarizes this clinical history, describing Sermorelin’s evaluation in the diagnosis and treatment of children with idiopathic growth hormone deficiency (Prakash A, Goa KL, BioDrugs. 1999;12(2):139-157; PMID 18031173).

That published clinical history relates to a pharmaceutical-sponsor development program and a distinct formulation and regulatory pathway — it does not establish safety or efficacy for research-grade Sermorelin sourced from a peptide vendor, and does not support human self-administration outside a formal clinical or medically supervised setting. Sermorelin as supplied here is not an FDA-approved drug for any indication, has not completed a current clinical-trial pathway, and is not evaluated by the FDA for safety or efficacy in humans or animals under this research-use-only sale.

This distinction matters for how findings from this page should be characterized. A researcher citing the pediatric GHD trials or the clinical review in a grant application or protocol design should describe them accurately as reflecting a historical pharmaceutical-development and diagnostic-use record, not as safety or efficacy data for the vendor-supplied research compound sold on this page.

Compared to Related Research Compounds

Sermorelin is frequently studied alongside, or compared against, other GH-axis research peptides that act through different receptor pathways. First Class Science supplies several related preparations for researchers running comparative studies:

Ipamorelin – 10mg is a selective ghrelin-receptor (GHS-R1a) agonist studied through a distinct receptor pathway from Sermorelin’s GHRH-receptor mechanism, and is commonly ordered alongside Sermorelin by labs running comparative receptor-pathway studies.

Tesamorelin and CJC-1295 are later-generation GHRH-analog research peptides structurally modified for extended receptor engagement relative to the native GHRH(1-29) sequence Sermorelin represents, and are frequently studied as comparators for structure-activity and half-life research.

Sermorelin Capsules supplies the same research peptide in an encapsulated format for laboratories that prefer not to reconstitute a lyophilized vial.

Each of these related preparations carries its own Certificate of Analysis and is subject to the same research-use-only terms described on this page.

Common Research Study Designs

Published studies referenced throughout this page typically fall into one of three designs: in vitro GHRHR receptor-binding and signaling assays; controlled pediatric clinical trials comparing GHRH(1-29) dosing regimens against direct GH administration; and diagnostic stimulation-test studies assessing pituitary somatotroph function. Understanding which design underlies a given finding is important context for interpreting the strength of any individual claim in the literature.

Frequently Asked Questions

What is the purity of this Sermorelin research peptide?
Every batch is independently verified via third-party HPLC and mass-spectrometry testing, with a Certificate of Analysis published for each lot.

How should Sermorelin research peptide be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is Sermorelin approved for human or animal use?
Sermorelin as sold here is a research-use-only compound, not an FDA-approved marketed drug. A historical pharmaceutical formulation (Geref) was studied and used diagnostically in children, but that record does not apply to this research-grade material, and it is sold exclusively for in vitro and laboratory research use.

Has Sermorelin been tested in humans at all?
Yes, extensively, in a distinct pharmaceutical-development context: published randomized trials examined GHRH(1-29) in children with growth hormone deficiency (PMID 8329826, PMID 8329830), and a clinical review summarizes this history (PMID 18031173). This research reflects a pharmaceutical-sponsor program using a different formulation than the research compound sold here.

How does Sermorelin differ from Ipamorelin?
Sermorelin is a GHRH-receptor agonist that mimics native growth-hormone-releasing hormone. Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist. Researchers frequently study them individually or in combination to model dual-receptor GH-axis signaling.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date, allowing researchers to independently verify the identity and purity of the specific batch they receive.

Can Sermorelin research peptide be shipped internationally?
Shipping availability and any import restrictions for research peptides vary by destination country and are subject to change; researchers should confirm their local import regulations for research-use-only compounds before ordering.

Shipping, Handling & Compliance

This Sermorelin research peptide ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Order tracking, batch-specific documentation requests, and general product questions can be directed to First Class Science customer support, which can confirm current lead times and any destination-specific documentation a receiving institution may require for its own compliance records.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or controlled clinical-trial contexts. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.